Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity
This RIC allo-HCT regimen for treatment of IEI had excellent OS with resolution of underlying immune abnormality, reconstitution of normal immune function, and low rates of GVHD. Future efforts will focus on optimizing engraftment in infants.
Authors
- Amanda Lipsitt (ORCID: https://orcid.org/0000-0002-3757-8493)
- Troy C. Quigg (ORCID: https://orcid.org/0000-0002-5268-7938)
- Robert J. Hayashi (ORCID: https://orcid.org/0000-0002-1140-1139)
- Lisa Murray
- Thomas Pfeiffer (ORCID: https://orcid.org/0000-0001-7793-669X)
- Melissa Mavers (ORCID: https://orcid.org/0000-0001-5452-9530)
- Sima Bhatt (ORCID: https://orcid.org/0000-0001-6751-5808)
- Jeffrey J. Bednarski (ORCID: https://orcid.org/0000-0001-6902-0876)
- Michael J. Eckrich (ORCID: https://orcid.org/0000-0002-8808-4266)
- Lisa Madden
- Feng Gao (ORCID: https://orcid.org/0009-0007-8910-4760)
- Shalini Shenoy (ORCID: https://orcid.org/0000-0002-9283-607X)
Institutions
- University of Wisconsin–Madison (US)
- Washington University in St. Louis (US)
- Sarah Cannon (US)
- United Electric Controls (United States) (US)
- 480 Biomedical (United States) (US)
- Methodist Children’s Hospital (US)
- Helen DeVos Children's Hospital (US)
- University of California, Davis (US)
Publication Details
- Journal
- Transplantation and Cellular Therapy
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1016/j.jtct.2025.11.028
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00